Compare stocks

H. Lundbeck A/S is a Danish pharmaceutical company focused on the research, development, production, and marketing of pharmaceuticals for the treatment of brain disorders. Headquartered in Copenhagen, Denmark, Lundbeck's core business includes a portfolio of products addressing conditions such as depression, anxiety, schizophrenia, Alzheimer's disease, and Parkinson's disease. The company has a significant presence in the neuropharmaceuticals industry, striving to deliver innovative solutions to patients with unmet medical needs. Lundbeck operates internationally, distributing its products across multiple markets, supported by its strategic positioning in research and development. Unique competitive strengths include its dedicated focus on central nervous system disorders and ongoing investments in innovative therapies.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.